Winning the Fight Against Type 1 Diabetes
Advancing Towards a World Without Type 1 Diabetes
Vactech’s Groundbreaking Preventive Type 1 Diabetes Vaccine Is Close to Reality
At Vactech, we are proud to lead the way in the development of a revolutionary multivalent vaccine designed to prevent type 1 diabetes. Our innovative, patented vaccine formulation specifically targets key enteroviruses, particularly Coxsackie B serotypes, which have been strongly associated with the onset of diabetes. In addition, our vaccine offers protection against several related enteroviral conditions, including myocarditis, meningitis, encephalitis, severe multiorgan infections, and potentially celiac disease.
“These important discoveries bring new hope to individuals and families affected by type 1 diabetes. By uncovering the role of enteroviruses in the earliest stages of the disease, we move closer to future vaccines and antiviral therapies — that can prevent its onset.” Heikki Hyöty - Chairman of the Board, Cofounder, Professor of Virology, MD, PhD
Validated by Clinical Success
Critical Milestone Achieved in Successful Clinical Trials
Backed by promising preclinical results, our vaccine’s potential to prevent type 1 diabetes is supported by favorable findings from a successful Phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT04690426), showcasing both safety and immunogenicity. This critical milestone reinforces the importance of our mission and the urgency of our work
Vactech’s vaccine not only addresses an urgent public health challenge but also opens new doors for growth with our expanding portfolio of vaccines, antivirals, and diagnostic solutions. Together, we can pioneer preventive solutions for autoimmune and infectious diseases, offering solutions to important global health problems.
Key Strengths of Our Breakthrough Vaccine
Vactech's Type 1 Diabetes (T1D) vaccine
Patented Composition
Our vaccine targets multiple enterovirus-related diseases simultaneously, effectively setting our innovative vaccine apart from traditional approaches used today.
Proven Effectiveness
Our vaccine has demonstrated preventive potential in both preclinical models and in comprehensive human clinical trials, confirming its promising efficacy and broad impact.
Favorable Safety Profile
Our vaccine shows excellent tolerability and a strong immune response, both of which have been clearly confirmed by extensive clinical trial results and safety assessments.
Broad Protection
Our vaccine is designed to provide robust defense against T1D, myocarditis, meningitis, encephalitis, life-threatening infant infections, and potentially even celiac disease.
Market Leadership
Our vaccine is positioned as the first-ever preventive vaccine for T1D, offering truly significant global market potential and a competitive advantage.
Proven Technology
Our vaccine utilizes proven technology similar to that of the widely successful polio vaccines, ensuring both reliability and trusted effectiveness worldwide.
Join Our Community
Join Us in Shaping the Future of Healthcare by Developing Innovative Solutions for Disease Prevention
Vactech’s success is built on close collaborations with leading international academic institutions and biotechnology industry partners. Our commitment to Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), combined with an extensive global network of scientific experts and Key Opinion Leaders, positions us to effectively translate cutting-edge science into impactful healthcare solutions.